Literature DB >> 6948942

Increased shunt through the patent ductus arteriosus after surfactant replacement therapy.

R I Clyman, A Jobe, M Heymann, M Ikegami, C Roman, B Payne, F Mauray.   

Abstract

Instillation of surfactant into the trachea of preterm infants with respiratory distress syndrome is associated with a 90% incidence of patent ductus arteriosus. We studied the effects of surfactant therapy on the ductus arteriosus in 12 preterm lambs. Flow across the ductus arteriosus and systemic blood flow were calculated from radioactive microsphere injections. All developed respiratory failure (pH less than 7.1, Paco2 greater than 60) by 30 minutes after birth. Between 30 and 60 minutes after birth, six lambs were treated with tracheal instillation of 50 mg/kg surfactant lipid. By two hours after birth, treated lambs differed significantly from controls in pH (7.27 +0.02 vs 6.97 +0.08) and Paco2 (43.3 +4.1 vs 85 + 15). There were no differences in Pao2 or PGE2 concentrations or ductus arteriosus resistance, but there was a significantly larger shunt through the ductus arteriosus in treated lambs. This increased shunt resulted from the significant drop in pulmonary vascular resistance and not from a change in patency of the ductus arteriosus. Surfactant replacement may require interventions directed specifically at the patent ductus arteriosus in sick preterm infants.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6948942     DOI: 10.1016/s0022-3476(82)80247-3

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  Exogenous surfactant treatments for neonatal respiratory distress syndrome and their potential role in the adult respiratory distress syndrome.

Authors:  T A Merritt; M Hallman; R Spragg; G P Heldt; N Gilliard
Journal:  Drugs       Date:  1989-10       Impact factor: 9.546

2.  Acute effects of instillation of surfactant in severe respiratory distress syndrome.

Authors:  H L Halliday; F B McCord; B G McClure; M M Reid
Journal:  Arch Dis Child       Date:  1989-01       Impact factor: 3.791

3.  Surfactant and patent ductus arteriosus.

Authors:  Abhay Kumar; Anil Lakkundi; Patrick J McNamara; Arvind Sehgal
Journal:  Indian J Pediatr       Date:  2010-01-20       Impact factor: 1.967

Review 4.  Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.

Authors:  K L Dechant; D Faulds
Journal:  Drugs       Date:  1991-11       Impact factor: 9.546

Review 5.  Surfactant replacement therapy.

Authors:  M J Kresch; W H Lin; R S Thrall
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

Review 6.  The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasia.

Authors:  Ronald I Clyman
Journal:  Semin Perinatol       Date:  2013-04       Impact factor: 3.300

7.  Early treatment of patent ductus arteriosus in premature infants with severe respiratory distress syndrome.

Authors:  G Pongiglione; M Marasini; G Silvestri; P Tuo; D Ribaldone; A Bertolini; L Garello-Cantoni
Journal:  Pediatr Cardiol       Date:  1988       Impact factor: 1.655

8.  Pulmonary haemodynamics after surfactant replacement in severe neonatal respiratory distress syndrome.

Authors:  M C Bloom; M Roques-Gineste; F Fries; M C Lelong-Tissier
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-09       Impact factor: 5.747

9.  Changes in pulmonary artery pressure in infants with respiratory distress syndrome following treatment with Exosurf.

Authors:  A H Hamdan; N J Shaw
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1995-05       Impact factor: 5.747

Review 10.  Surfactant treatment for respiratory distress syndrome: a review.

Authors:  C J Morley
Journal:  J R Soc Med       Date:  1984-09       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.